Effect of High-Dose Angiotensin II Receptor Blocker Monotherapy Versus ARB Plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese Elderly High-Risk Hypertensive Patients - OSCAR


Although the benefits of high-dose angiotensin-receptor blocker (ARB) therapy in patients with diabetic nephropathy and congestive heart failure (CHF) are well known, it is unclear if this is true for high-risk patients with hypertension as well. The current trial sought to compare outcomes with high-dose ARB versus low-dose ARB, along with a calcium channel blocker (CCB), in elderly Japanese patients with at least one cardiovascular (CV) risk factor.